• In late June 2026, Eli Lilly reported strong Q1 results, advanced its obesity and diabetes franchise with Medicare’s GLP‑1 Bridge program, and gained a positive EMA opinion for Jaypirca in chronic lymphocytic leukemia alongside several new R&D collaborations and product updates.
• Taken together, these developments broaden access to key therapies, deepen Lilly’s oncology and immunology pipeline, and highlight its push to diversify beyond GLP‑1 medicines while scaling global manufacturing.
• We’ll now examine how expanded Medicare GLP‑1 access, in particular, may reshape Eli Lilly’s existing investment narrative and long‑term outlook.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you have to believe its incretin franchise can justify a premium valuation while newer oncology, immunology, and neuroscience assets steadily reduce dependence on GLP‑1s. The key near term catalyst remains expanded Medicare GLP‑1 access, while the biggest risk is mounting pricing and policy scrutiny on obesity and diabetes drugs. Recent June announcements largely support the diversification story without materially changing that core risk reward balance.

Among the latest updates, the positive EMA opinion for Jaypirca in chronic lymphocytic leukemia looks most relevant. It reinforces Lilly’s effort to build a second pillar in oncology that is less exposed to GLP‑1 reimbursement swings, while the Medicare GLP‑1 Bridge program reshapes short term expectations around access and volumes in obesity more directly than partnerships, dividends, or early stage collaborations.

Yet behind the GLP‑1 access headlines, investors should also be aware of growing scrutiny of drug costs and obesity safety that could eventually...

Eli Lilly's narrative projects $113.8 billion revenue and $46.8 billion earnings by 2029.

Uncover how Eli Lilly's forecasts yield a $1219 fair value, in line with its current price.

Exploring Other Perspectives

While consensus sees strong GLP 1 demand as the main engine, the most bearish analysts already assumed only about US$102.4 billion of revenue and US$40.2 billion of earnings by 2029, reminding you that views on pricing pressure and R&D risk can differ widely and may shift again after this Medicare access news.

Explore 20 other fair value estimates on Eli Lilly - why the stock might be worth 26% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.